The global artificial retina market size is valued at USD 3.3 million in 2026 and is projected to grow from USD 6.9 million in 2027 to USD 25.2 million by 2033, at a CAGR of 33.6% from 2027 to 2033. Europe dominated the market, accounting for the largest revenue share of 100.0% in 2026. Artificial retina systems, also known as retinal prostheses or retinal implants, are implantable electronic devices designed to stimulate surviving retinal neurons or downstream visual pathways when photoreceptor cells have been permanently damaged.
These systems typically comprise an implantable microelectronic chip, an external camera, an image processing unit, and wireless communication technology that together convert visual information into electrical signals interpretable by the visual system. The current commercial landscape for artificial retina systems remains highly nascent. As of 2026, PRIMA is the only artificial retina system that has entered commercialization, following the receipt of CE Mark approval in July 2026 for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
Commercial availability is currently limited to Europe, with initial rollout focused on selected specialized retinal centers while reimbursement processes and broader site activation continue across the region. Earlier-generation retinal prostheses, including the Argus II, Alpha IMS, Alpha AMS, and IRIS II systems, have been discontinued due to limited commercial adoption and strategic business decisions, resulting in a significant gap between historical and current commercialization. Consequently, the global artificial retina industry is presently driven primarily by the initial European commercialization of PRIMA, with future market expansion expected to depend on additional regulatory approvals, geographic expansion, reimbursement adoption, and the commercialization of next-generation retinal prosthesis technologies.
Artificial retina implant (ARI) technologies are primarily being developed for patients with retinitis pigmentosa (RP), advanced age-related macular degeneration (AMD), Stargardt disease, and other inherited retinal dystrophies, for whom conventional medical or surgical treatments offer limited or no restoration of vision. Growing investments in neurotechnology, bioelectronics, and vision restoration research are supporting the continued development of the artificial retina implant (ARI) market. One of the primary factors driving market growth is the increasing prevalence of retinal degenerative diseases globally. Inherited retinal degenerations affect more than 5.5 million people globally, while age-related macular degeneration remains one of the leading causes of irreversible blindness among older adults.
Population aging, greater awareness of inherited retinal disorders, improved genetic testing, and earlier diagnosis are expanding the pool of patients who may benefit from advanced vision restoration technologies. For instance, In January 2026, the New England Journal of Medicine (NEJM) published the PRIMA clinical trial and an accompanying editorial recognizing the PRIMA subretinal photovoltaic implant as the first treatment to restore vision in patients with advanced geographic atrophy due to age-related macular degeneration (AMD). The study demonstrated clinically meaningful improvements in visual acuity in the majority of implanted patients, marking a significant milestone in the advancement of artificial retina technology and vision restoration research.
Another major driver is the rapid advancement of retinal prosthesis technology and neuroengineering. Continuous innovations in microelectronics, photovoltaic implants, wireless power transfer, high-density electrode arrays, artificial intelligence-enabled image processing, and miniaturized implant designs are significantly improving the performance and safety of artificial retina systems. These technological developments are enabling higher visual resolution, improved implant stability, and enhanced patient outcomes compared with earlier generations of retinal prostheses.
These systems typically comprise an implantable microelectronic chip, an external camera, an image processing unit, and wireless communication technology that together convert visual information into electrical signals interpretable by the visual system. The current commercial landscape for artificial retina systems remains highly nascent. As of 2026, PRIMA is the only artificial retina system that has entered commercialization, following the receipt of CE Mark approval in July 2026 for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
Commercial availability is currently limited to Europe, with initial rollout focused on selected specialized retinal centers while reimbursement processes and broader site activation continue across the region. Earlier-generation retinal prostheses, including the Argus II, Alpha IMS, Alpha AMS, and IRIS II systems, have been discontinued due to limited commercial adoption and strategic business decisions, resulting in a significant gap between historical and current commercialization. Consequently, the global artificial retina industry is presently driven primarily by the initial European commercialization of PRIMA, with future market expansion expected to depend on additional regulatory approvals, geographic expansion, reimbursement adoption, and the commercialization of next-generation retinal prosthesis technologies.
Artificial retina implant (ARI) technologies are primarily being developed for patients with retinitis pigmentosa (RP), advanced age-related macular degeneration (AMD), Stargardt disease, and other inherited retinal dystrophies, for whom conventional medical or surgical treatments offer limited or no restoration of vision. Growing investments in neurotechnology, bioelectronics, and vision restoration research are supporting the continued development of the artificial retina implant (ARI) market. One of the primary factors driving market growth is the increasing prevalence of retinal degenerative diseases globally. Inherited retinal degenerations affect more than 5.5 million people globally, while age-related macular degeneration remains one of the leading causes of irreversible blindness among older adults.
Population aging, greater awareness of inherited retinal disorders, improved genetic testing, and earlier diagnosis are expanding the pool of patients who may benefit from advanced vision restoration technologies. For instance, In January 2026, the New England Journal of Medicine (NEJM) published the PRIMA clinical trial and an accompanying editorial recognizing the PRIMA subretinal photovoltaic implant as the first treatment to restore vision in patients with advanced geographic atrophy due to age-related macular degeneration (AMD). The study demonstrated clinically meaningful improvements in visual acuity in the majority of implanted patients, marking a significant milestone in the advancement of artificial retina technology and vision restoration research.
Another major driver is the rapid advancement of retinal prosthesis technology and neuroengineering. Continuous innovations in microelectronics, photovoltaic implants, wireless power transfer, high-density electrode arrays, artificial intelligence-enabled image processing, and miniaturized implant designs are significantly improving the performance and safety of artificial retina systems. These technological developments are enabling higher visual resolution, improved implant stability, and enhanced patient outcomes compared with earlier generations of retinal prostheses.
Global Artificial Retina Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2027 to 2033. For this study, the analyst has segmented the global artificial retina market report based on product, disease indication, end-use, and region:Product Outlook (Revenue, USD Million, 2027 - 2033)
- Epiretinal Implants
- Subretinal Implants
- Suprachoroidal Implants
Disease Indication Outlook (Revenue, USD Million, 2027 - 2033)
- Retinitis Pigmentosa
- Dry Age-Related Macular Degeneration (Geographic Atrophy)
- Stargardt disease
- Other Inherited Retinal Dystrophies (IRD)
End Use Outlook (Revenue, USD Million, 2027 - 2033)
- Hospitals
- Specialty Eye Clinics
- Others
Regional Outlook (Revenue, USD Million, 2027 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Norway
- Denmark
- Sweden
- Asia Pacific
- China
- Japan
- South Korea
- Thailand
- Australia
- India
- Latin America
- Brazil
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Artificial Retina Market Variables, Trends & Scope
Chapter 4. Artificial Retina Market: Product Estimates & Trend Analysis
Chapter 5. Artificial Retina MaDisease Indication Estimates & Trend Analysis
Chapter 6. Artificial Retina Market: End Use Estimates & Trend Analysis
Chapter 7. Artificial Retina Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Science Corporation
- Cortigent (Subsidiary of Vivani Medical, Inc.)
- Nano Retina
- Bionic Vision Technologies
- iBIONICS
- Optobionics Corporation
- Monash Vision Group
- NIDEK CO., LTD.
